A B S T R A C T Patients with the "non-salt-losing" form of the adrenogenital syndrome were studied before and after suppression of adrenal cortical activity with carbohydrate-active steroids. The response of aldosterone secretion to sodium deprivation was measured; in some patients response to adrenocorticotropic hormone (ACTH) was measured as well.
A B S T R A C T Patients with the "non-salt-losing" form of the adrenogenital syndrome were studied before and after suppression of adrenal cortical activity with carbohydrate-active steroids. The response of aldosterone secretion to sodium deprivation was measured; in some patients response to adrenocorticotropic hormone (ACTH) was measured as well.
The aldosterone secretion was normal and responded normally to sodium deprivation in all patients studied during suppression with carbohydrate-active steroids. This finding suggests that 21-hydroxylation of progesterone is normal in this syndrome.
The sole abnormality in the production of aldosterone in these patients was found to be excessive secretion of aldosterone while they were not receiving suppressive doses of carbohydrate-active steroids. This finding strongly supports the view that the biogenetic pathways through which aldosterone is produced from progesterone are intact in this syndrome.
No patient showed hypertension or hypokalemic alkalosis despite very high aldosterone secretion rates. This observation suggests that the hyperaldosteronism is secondary to a tendency to sodium loss in the patient whose ACTH production is not suppressed.
INTRODUCTION
The abnormalities of steroidogenesis which characterize congenital adrenal hyperplasia include (a) a defect in the biosynthesis of cortisol, (b) decrease in normal regulatory inhibition of adrenocorticotropic hormone (ACTH) with increased secretion of ACTH and (c) overproduction of steroids "proximal" to the site of the block in the biogenetic pathway of cortisol. Since overproduction of pregnanetriol 1 and of pregnanetriolone (1) has been demonstrated in this disease, it has been assumed that the block in steroidogenesis -involves the 21-hydroxylation of 17a-hydroxyprogesterone (2) . A defect in 21-hydroxylation of 17a-hydroxyprogesterone has been shown in vitro for two patients with the "salt-losing" form of congenital adrenal hyperplasia (3) .
A simple defect in the 21-hydroxylation of 17a-hydroxyprogesterone will not explain the difference between the "salt-losing" form of congenital adrenal hyperplasia, in which secretion of aldosterone is defective (4) , and the "non-salt-losing" form, in which there is no defect in aldosterone secretion (see below). We have suggested (4) that patients with the "salt-losing" variety of the disorder may have a second enzymatic defect, namely, a relative inability to perform 21-hydroxylation of progesterone. As a corollary of this hypothesis, the production of aldosterone by patients with the "non-salt-losing" syndrome should be excessive. A biosynthetic block in 21-hydroxylation of 17a-hydroxyprogesterone should result in excessive quantities of 17a-hydroxyprogesterone, and this in turn would lead to excessive quantities of progesterone; in the absence of a biosynthetic block between progesterone and aldosterone, aldosterone production should be increased. In the present studies, we have explored this hypothesis. We have examined further the effect of sodium deprivation on aldosterone secretion in patients with "non-saltlosing" congenital adrenal hyperplasia (a) while they received no treatment with adrenal steroids, (b) during stimulation with exogenous ACTH and (c) during continuous treatment with exogenous carbohydrate-active steroids to inhibit endogenous ACTH production, and thereby inhibit any consequent change in production of ACTH-dependent "salt-losing" hormones.
METHODS
12 patients with "non-salt-losing" congenital adrenal hyperplasia were studied. Table I lists the essential clinical and laboratory data on each patient. Two experimental designs were employed. The first may be seen by inspection of Table II and III and Fig. 1 . Treatment was discontinued for as long a period as possible before study. The period ranged up to 22 yr.2 Patients were given a metabolic diet containing 60 mEq or more of sodium per m' of body surface each day; without exception, they had been on ad lib. diets before this study. All studies were carried out with standard metabolic regimen in an air-conditioned unit in which patients remained throughout the study. Urinary sodium and potassium was measured daily, serum potassium and carbon dioxide content and hematocrit at intervals, and blood pressure at least 4 times a day. Aldosterone secretion rate was measured. ACTH was then administered for a 4 day period at a dosage of 40 U/day intramuscularly. Aldosterone secretion rate was again measured on day 2 and, in all patients except two, on day 4 of treatment with ACTH. Aldosterone secretion rate was again measured in most cases 2 or 3 days after ACTH was stopped. Throughout this period, the initial sodium intake was maintained. Dietary sodium was then lowered to 9 mEq/ day, and aldosterone secretion rate was again measured on days 3-5 of this regimen (Table III) .
The second protocol may be seen by inspection of Table IV and of Fig. 2 . On this protocol, patients were treated continuously with prednisone at dosages (5, 10, or 15 mg/day) sufficient to lower 17-ketosteroid excretion to normal. They were depleted of sodium as described above by eating a diet containing 9-14 mEq of sodium per day for periods of 4-8 days. Aldosterone secretion rate was measured in each. The patients then received increments of dietary sodium of 60 or more mEq per m' of body surface per day, and aldosterone secretion rate was 2 Patient D.M. could not discontinue exogenous replacement steroid but was given exogenous ACTH before admission, and the steroid was discontinued on the day of admission. Thus she was off steroid for 6 days before the first secretion rate. Aldosteronism in "Non-Salt-Losing" Congenital Adrenal Hyperplasia measured on the 4th day of this regimen. Two of these carried out on the 24-hr urine collected immediately after patients were studied by sodium deprivation both "off" the specimen used for the secretion rate. and "on" suppressive therapy (Fig. 3) . A third child (a The radiochemical purity of the final eluate of aldosmale pseudohermaphrodite with normal adrenal func-terone monoacetate used to measure secretion rates was tion) was studied in an identical manner as shown in verified on 15 specimens by measurement of the 14C/5H ratio and that of various derivatives, purified through adAldosterone secretion rate was measured as described ditional chromatographic procedures; in particular some previously (4) . In this study, all collections were carried of the specimens allowed as many as three additional out for complete 24-hr periods, and the metabolite of al-chromatographic separations (or a total of seven). The dosterone which was measured (the 18-glucuronide) was results are shown in Table V . They indicate that reavirtually all excreted within 24 hr. This excretion was sonable radiochemical purity is achieved by the methods demonstrated by the procedure previously described (4), employed. In the patients receiving prednisone at dosages sufficient to decrease 17-ketosteroid excretion to normal (Table IV) , aldosterone secretion rates ranged from 26 pug/day in J.G. to 121 pg/day in B.W. These values fall within the normal range for patients receiving, as these were, 60 mEq or more of sodium per m2 each day. In each patient subjected to sodium restriction while suppression Fig. 3 . The aldosterone secretion rate was two to three times higher with sodium deprivation than it was with sodium loading. All values, however, were approximately twice as high without suppression by prednisone as they were during suppression. In contrast, the control patient showed no significant change between the secretion rates with sodium loading before and during prednisone therapy but demonstrated a significant increase in the secretion rate during sodium depreviation and prednisone therapy (Fig.  4) 4 Design of experiment and results of study of control subject both with and without steroid suppression on low and high sodium intake.
decrease. In two patients (B.M. and S.M.) the aldosterone secretion rate decreased between day 2 and day 4. This last is the usual pattern of response in normal subjects (6) and has been observed also in the adrenogenital syndrome (7) .
Despite the high values for aldosterone secretion rate found in some of these subjects while they were not receiving suppressive doses of carbohydrate-active steroids, all patients demonstrated normal blood pressure, and no patient developed hypokalemia or alkalosis (Tables II and III) . DISCUSSION It is clear from the evidence presented and from previous studies (8, 9) that the biosynthetic pathways for aldosterone production are not defective in the "non-salt-losing" form of the adrenogenital syndrome. Thus (9) . If there were in these patients a block in the 21-hydroxylation of progesterone, the inhibition of ACTH production with carbohydrateactive steroids, superimposed on such a block, should lead to the inhibition of aldosterone production so that subnormal quantities would be produced. The normal values found with suppression and the normal response to sodium deprivation despite such suppression argue strongly for normal biogenetic pathways from progesterone to aldosterone in this syndrome.
The results (Table II) reveal a surprising discrepancy between the aldosterone secretion rates on the one hand, and the clinical and serum chemical findings on the other. Whereas aldosterone se- FIGURE 5 Summary of all data on patients studied without steroid suppression. AG non-salt-losing refers to patients on the present study. Normal subjects are normal volunteers studied while receiving 109 mEq of sodium a day, followed by 9 mEq of sodium for at least 4 days after mercurial diuretic. AG salt-losing indicates data from patients with sodium-losing adrenogenital syndrome from J. Clin. Invest. 1965. 44: 957. 9 SODIUM INTAKE (mEq) creton rates reached values as high as 1697 ug/ day in the unsuppressed state despite the ingestion of average amounts of sodium, all patients remained consistently normotensive, and no patient developed hypokalemia or alkalosis. Thus, it appears clear on clinical grounds that one of two situations must obtain: either the actual production rate of aldosterone is not accurately reflected by the aldosterone secretion rate procedure based upon a urinary metabolite, or the action of aldosterone is inhibited in these patients. Increased excretion of urinary estriol is well documented in patients with congenital adrenal hyperplasia (1 in turn leads to an increase in the production of progesterone and of 17-hydroxyprogesterone as demonstrated by the excretion of pregnanediol (13) , pregnanetriol, and pregnanetriolone in increased quantities (1) . The sequence of events in the "non-salt-losing" form of the adrenogenital syndrome might be explained in two different ways (Fig. 6) ; the clinical consequences may allow a choice between these sequences. In the first place, overproduction of progesterone might induce overproduction of deoxycorticosterone, of corticosterone, of 18-hydroxycorticosterone, and finally of aldosterone as a consequence of the overabundance of precursor. As noted above, it is clear that the pathways between progesterone and aldosterone are not impaired in these patients, and thus there is no reason a priori to reject this hypothetical sequence (Fig. 6 A) . Alternatively, progesterone and 17-hydroxyprogesterone, produced in excess by the same mechanism, might produce loss of sodium (14) (15) (16) by antagonizing the effects of endogenous aldosterone. This, by leading to a relative sodium depletion, might lead to the overproduction of aldosterone as a compensatory phenomenon.
It is of interest to examine the consequences of these two alternative sequences to explain the overproduction of aldosterone in the "non-saltlosing" adrenogenital syndrome (Fig. 6 ). According to sequence A ("Biogenetic"), the production of aldosterone is a direct biogenetic consequence of the overproduction of precursors. Accordingly, the effect of this aldosterone should be apparent from its actions on the organism or on the renal tubules. It would be reasonable to anticipate hypokalemic alkalosis, hypertension, a fixed rate of aldosterone secretion, or a combination of all three, if this were the sole explanation for the aldosteronism.
Alternatively, according to sequence B ("Physiologic") overproduction of aldosterone represents an attempt to compensate for the sodium loss which results in turn from the overproduction of weak sodium-losing steroids such as progesterone and 17-hydroxyprogesterone. As physiologic compensation is virtually never "complete," it would be reasonable to suppose that the amounts of aldosterone produced might just fail to compensate for the loss of sodium; despite the excessive quantities of aldosterone presented to the tubules the sodium-losing steroids would also block sodiumfor-hydrogen and sodium-for-potassium exchange and thus prevent the hypokalemic alkalosis that one would anticipate with an "autonomous" aldosteronism of the degree found in these patients.
In all patients an increase in sodium intake decreased aldosterone secretion (or sodium deprivation stimulated it) even when there was no suppression of adrenocortical activity by carbohydrateactive steroids. If sequence A were responsible for the overproduction of aldosterone, an increase in dietary sodium alone should have little effect on the overabundance of precursors to the biogenesis of aldosterone and thus should not decrease its production so effectively. Accordingly, both lines of evidence favor sequence B; these results lend indirect support to the hypothesis that "sodium-losing" steroids (such as progesterone) play an important role in the increased aldosterone production in the "non-salt-losing" adrenogenital syndrome as previously suggested (8) .
These results showing excessive production of aldosterone in the "non-salt-losing" variety of the adrenogenital syndrome stand in striking contrast to those in the "salt-losing" variety of the syndrome, in which aldosterone secretion is very low and shows little response to sodium deprivation (4) . Furthermore, it appears clear that the two syndromes are genetically -distinct from each other ( 17) although there are reports which tend to question this conclusion (18) . It has been suggested that the difference between the two syndromes is one of degree of block in 21-hydroxylation, the sodium-losing variety representing the more severe block (2, 8) . This explanation appears unlikely in view of the excessive production of aldosterone in "non-salt-losing" variety. Earlier results suggested that secretion of cortisol was defective in the sodium losers and normal, albeit limited, in the "non-salt-losers" (2) . Subsequent studies have demonstrated normal cortisol secretion in the "nonsalt-losing" form with limited response to ACTH and low or normal cortisol secretion in the saltlosing form with minimal response to ACTH (19, 20) .
In view of all the evidence it appears not unlikely that there are two separate isozymes of the 21-hydroxylase enzyme for C21 steroids. Thus the "non-salt-losing" patients may produce an isozyme defective in 21-hydroxylation of 17a-hy-droxyprogesterone alone, whereas those with the salt-losing form of the disease may produce an isozyme possessing a defect which prevents the 21-hydroxylation of both progesterone and 17a-hydroxyprogesterone. This hypothesis would explain the presently available genetic and clinical data.
